Tag: GlobeNewswire

Helsinki hotel project expands the reach of LiqTech’s ceramic membrane filtration technology

BALLERUP, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its first commercial Aquatics order in Finland for the swimming pool at Original Sokos Hotel Presidentti in Helsinki. Secured through the Company’s Pool4You partnership, this order extends LiqTech’s commercial pool presence into a new market and advances its strategy of expanding adoption of its proprietary silicon carbide membrane technology.

LiqTech’s QlariFlow™ Aquatics platform combines silicon carbide ceramic membranes with a compact, modular system design to address the water quality and operating requirements of commercial pools. The technology is designed to deliver consistent filtration while helping operators reduce water, energy and chemical consumption compared with conventional filtration approaches. Its space-efficient configuration also supports installation in facilities where plant room space is limited, making it suitable for both new pool projects and upgrades to existing facilities.

These capabilities are central to LiqTech’s Aquatics growth strategy. By bringing its membrane technology and filtration systems to more commercial pool applications, the Company aims to meet demand for reliable water treatment and more efficient facility operation. The Helsinki project, which specifies a 2 × 2 membrane configuration plus AutoCIP, will bring LiqTech’s filtration technology to a commercial pool in Finland and serve as an example for other pool operators considering similar upgrades.

“This first order in Finland reflects our progress in bringing LiqTech’s ceramic membrane technology to more commercial pool markets,” said Fei Chen, CEO of LiqTech. “Our value starts with the technology and the system we deliver. We combine precise filtration with a compact design to help pool operators maintain water quality while using resources more efficiently. The Original Sokos Hotel Presidentti project is another step in expanding the reach of these capabilities, with Pool4You providing the local expertise and customer access to support our growth in Finland.”

The order follows the September 1, 2026 expansion of LiqTech’s Pool4You partnership. With more than four decades of pool water treatment experience, Pool4You provides established local relationships and project support that complement LiqTech’s technology. Its work encompasses over 80% of Finnish public swimming pool water treatment systems.

About LiqTech International Inc.

LiqTech International, Inc., a Nevada corporation, is a high-tech filtration technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech’s silicon carbide membranes are designed to be used in the most challenging purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech’s SiC liquid membrane technology with the Company´s extensive systems design experience and capabilities, LiqTech offers unique, modular designed filtration solutions for the most difficult water purification applications.

For more information, please visit www.liqtech.com 

Follow LiqTech on Linkedln:https://www.linkedin.com/company/liqtech/

Follow LiqTech on Twitter: https://twitter.com/LiqTech

Forward–Looking Statement

This press release contains “forward-looking statements.”  Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements.  Readers are urged to carefully review and consider the various disclosures made by us in the reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation, and cash flows.  If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.  Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

We assume no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

LiqTech Company Contact                                         
Susan Keegan Elleskov
Head of Marketing
LiqTech International, Inc.
Phone: +45 31315941
www.liqtech.com

LiqTech Investor Contact                                         
Robert Blum
Lytham Partners, LLC                                 
Phone: 602-889-9700
liqt@lythampartners.com

• Collaborations at Applied’s EPIC Center in Silicon Valley and Intel’s R&D campus in Oregon aim to develop breakthroughs in next-generation transistors, interconnects and advanced packaging technologies for AI chips and systems 
• Collaboration builds on the companies’ long history of working together to solve complex semiconductor device scaling challenges

SANTA CLARA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Applied Materials, Inc. (Nasdaq: AMAT), the leader in materials engineering for the semiconductor industry, today announced it is working with Intel Corporation (Nasdaq: INTC) to accelerate development of chipmaking innovations for next-generation transistors, interconnects and advanced packaging technologies. The collaboration will bring together cutting-edge capabilities from Applied’s EPIC Center in Silicon Valley and Intel’s R&D campus in Hillsboro, Oregon to shorten time-to-market of advanced semiconductor technologies essential to AI computing.

“Applied and Intel share a decades-long history of deep collaboration focused on pushing the boundaries of materials engineering to advance the semiconductor roadmap,” said Gary Dickerson, President and CEO of Applied Materials. “Bringing our teams together at the EPIC Center will deepen that partnership and accelerate the transistor, interconnect and packaging innovations needed to drive the future of AI computing.”

“The demand for AI computing is driving the need for major advances in performance, power efficiency, and packaging. Intel is focused on delivering those innovations and doing it in close collaboration with partners across the ecosystem,” said Lip-Bu Tan, CEO of Intel. “Applied Materials is an important partner, and we look forward to expanding our work together at the EPIC Center to help accelerate the path from the lab to high-volume manufacturing in the United States.”

Teams from Applied Materials and Intel are collaborating on next-generation materials, process technologies and device architectures for advanced logic nodes targeting AI workloads, and will continue this work at the EPIC Center. The collaboration spans both front-end and back-end-of-line advancements, including interconnect scaling. The collaboration also involves development of advanced packaging technologies for Foveros-based 3D stacking, supporting higher interconnect density, improved power delivery, and enhanced thermal performance for high-performance compute platforms designed to accelerate emerging agentic AI workloads.

“With the chipmaking roadmap becoming more complex at each process node, accelerating innovations in semiconductor devices, interconnects and packaging requires deeper collaboration across R&D and manufacturing,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “We look forward to working closely with Intel as a founding partner of the EPIC Center to shorten development cycles and bring new technologies to market faster.”

“Accelerating our R&D to keep pace with the rapid buildout of AI infrastructure is critical to delivering the technology, manufacturing excellence and foundry services our customers expect from Intel Foundry,” said Naga Chandrasekaran, Executive Vice President, Chief Technology and Operations Officer and General Manager of Intel Foundry. “Applied Materials’ new EPIC Center provides an environment where our teams can collaborate even more closely and at higher velocity to accelerate materials development and process innovations.”

Applied’s new EPIC (Equipment and Process Innovation and Commercialization) Center in Silicon Valley, which is scheduled to be operationally ready this year, is designed from the ground up to dramatically reduce the time it takes to commercialize breakthrough technologies from early-stage research to full-scale manufacturing. For chipmakers, the EPIC Center will provide earlier access to Applied’s R&D portfolio, faster cycles of learning and accelerated transfer of next-generation technologies into high-volume manufacturing, within a secure collaborative environment. In addition, the co-innovation programs at the EPIC Center will provide Applied with greater multi-node visibility to guide R&D investments while increasing R&D productivity and value sharing.

Forward-Looking Statements
This press release contains forward-looking statements, including those regarding Applied’s investment and growth strategies, the development of new materials and technologies, industry outlook and technology requirements, the plans and expectations for the EPIC Center, and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the demand for semiconductors and customers’ technology requirements; the ability to develop new and innovative technologies; the ability to obtain and protect intellectual property rights in key technologies; the ability to achieve the objectives of the EPIC Center; and other risks and uncertainties described in Applied’s filings with the Securities and Exchange Commission, including Applied’s most recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and Applied assumes no obligation to update them.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Contacts:

Applied Materials
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

Chairman and CEO Matt Edelman on why the proposed transaction transforms what Super League can become in its next chapter

SANTA MONICA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Super League Enterprise, Inc. (Nasdaq: SLE) (“Super League” or the “Company”), an audience intelligence and media activation company trusted by global brands to reach and engage people who play video games across the digital advertising landscape, issued a letter to stockholders from the Company’s Chairman and Chief Executive Officer, Matt Edelman.

Dear Fellow Stockholders,

On August 18, 2026, Super League announced what I believe is the most consequential transaction in our history.

With approval from you, our stockholders, at our 2026 Annual Meeting on October 16, 2026, and satisfaction of other closing conditions, we are on track to become part of a global platform with access to public capital markets in both the U.S. and Japan. More specifically, after closing, we would remain a Nasdaq-listed company, subject to the approval of Nasdaq, while also becoming a company controlled by Metaplanet Inc. (“Metaplanet”) (TSE:3350), a Tokyo Stock Exchange-listed company and the third largest corporate Bitcoin holder in the world (as of August 18, 2026).

Also upon closing, we would have a new name – Superplanet, Inc. – representing both our legacy and our new partnership with Metaplanet.

There are many details to this transaction, all available in our definitive proxy statement filed on September 25, 2026. I want to use this letter to focus on something critically important: why we believe it can fundamentally change the opportunity for our stockholders.

For the past eighteen months, my focus has been on ensuring Super League could pursue an open-ended future enabled by a stable foundation. We eliminated debt, reduced costs, simplified our capital structure and strengthened the underlying business. We did that work because it was necessary. But it also created new possibilities – possibilities uniquely available to a clean, compliant, unencumbered Nasdaq company in a market that rewards scale, business model diversification, cost discipline and global relevance.

This transaction represents that exact type of opportunity, offering Super League and our stockholders a future of an entirely different scale.

I appreciate having this chance to share more about why we are so invigorated by this transformational trajectory.

A Commitment Designed for the Long Term

It is important to understand what Metaplanet is bringing to Super League and the conviction behind that commitment.

In just over two years, Metaplanet has built one of the largest corporate Bitcoin treasuries in the world. Upon successfully closing this transaction, Metaplanet is expected to contribute 2,100 of its own Bitcoin to Super League and become the Company’s controlling stockholder. Equally important, Metaplanet has agreed to a five-year lock-up covering its shares of common stock received at closing, as well as shares of common stock it would receive through the exercise or conversion of additional securities contemplated by the transaction.

That matters.

Metaplanet is not approaching Super League as a short-term financial investment. It is committing its Bitcoin, its balance sheet, its capital markets expertise and learnings from both successes and setbacks in building one of the largest corporate Bitcoin treasuries. Most meaningful to SLE stockholders, Metaplanet is locking in its equity ownership for an initial period of five years — reflecting Metaplanet’s long-term commitment to Super League rather than prioritizing near-term liquidity.

That kind of commitment doesn’t happen by accident, and it doesn’t happen without conviction.

We also believe Metaplanet’s decision to build its U.S. platform through Super League is a validation of what our team has accomplished. Super League brings an established management team and operating infrastructure, a decade of experience working with many of the world’s largest consumer brands, and an understanding of the psychographic, behavioral, and lifestyle traits of the global population of consumers who play video games. We see that kind of reach into a digitally native community as an advantage and believe it could position Superplanet to lead in introducing Bitcoin, and the companies building around it, to the next generation.

We’re not trading in our assets. We’re building on top of them.

Why Bitcoin

I want to spend a moment here, because not every stockholder reading this letter follows Bitcoin closely, and you shouldn’t need to do so in order to understand the fundamental reasons for this transaction.

Start with something more familiar: money itself. Governments around the world have spent recent years expanding the supply of their currencies to meet specific needs. While the benefits occupy most of the headlines, there is also a cost. When more currency enters a system, each existing unit tends to be worth a little less, which has the effect of lowering the value of what people have worked to save.

This isn’t a new phenomenon, but the pace of it has accelerated, and it’s part of why a growing number of companies, central banks and long-term investors have started paying closer attention to assets that cannot simply be increased on demand.

Bitcoin is one of those assets, and in our opinion, a key asset that a company in today’s global economy can hold on its balance sheet. We believe Bitcoin is a highly liquid store of value, with supply that is fixed by code rather than policy. That doesn’t make it risk-free. However, it can be a credible solution to a real and growing problem.

We’re not asking our stockholders to become Bitcoin experts or to agree with every argument its advocates make. We’re asking you to consider the value of supporting a company that takes seriously how much harder a saved dollar has to work today just to be worth the same tomorrow.

Bitcoin’s price can be volatile, sometimes sharply so, and nothing here is a prediction about where it would trade next month, next quarter or beyond. Our conviction rests on its potential long-term properties, not its short-term path. And we’re not carrying that conviction alone. With the approval of our stockholders and satisfaction of other closing conditions, we would stand as part of a new global platform with Metaplanet, whose disciplined stewardship of a corporate Bitcoin treasury gives us a model already operating successfully at scale.

Two Businesses, One Company

I want to be direct about something important: this is not a pivot away from Super League’s operating business. With Metaplanet as our partner and parent company, we would be launching an additional business line, running in parallel with what we already do every day.

While the Bitcoin treasury would be our primary driver of enterprise growth, we expect our gaming media and advertising business to continue alongside it, with continuity across our management team, employees, customers and brand partners, as described in our definitive proxy statement. We remain focused on our path to stronger financial outcomes. Nothing about our commitment to stabilizing and improving the results of that business changes as a result of this transaction.

Alongside it, we would be adding a second, powerful new engine: a Bitcoin treasury, set to be seeded with an investment of 2,100 Bitcoin – worth approximately $132 million as of the closing price of Bitcoin on the Coinbase Exchange at 4:00 p.m. (New York City time) on August 14, 2026 – the largest single investment in Super League’s history. While the value of Bitcoin remains volatile, it is worth noting the value of 2,100 Bitcoin as of the closing market price of Bitcoin on the Coinbase Exchange at 4:00 p.m. (New York City time) on October 2, 2026 increased to approximately $179 million. 

The transaction structure also provides for warrants and other investment rights that could potentially provide substantial additional capital to Superplanet over time if exercised, as described in our definitive proxy statement. Superplanet also would be able to pursue independent direct capital raises based on market conditions. We would intend to pursue such opportunities thoughtfully, favoring structures that grow Bitcoin per share for our stockholders.

These two businesses are not as disconnected as they may first appear. The consumers we reach every day – people who play video games – demonstrate ongoing comfort with digital ownership, specifically of assets within video games, which they choose to purchase, trade, and value based on a combination of personal conviction and in-game dynamics. We believe that behavior creates real commercial opportunity. We’ve spent years helping brands build relationships with gaming audiences; we see the same potential in helping expand Bitcoin awareness and ownership within that same audience, and in time, developing unique programs that bring brands into the Bitcoin economy. We don’t need to force these connections, but where they may meet naturally, we would strive to be first.

Two businesses, each capable of creating increasing value on its own terms, operating under one roof.

Changing the Ceiling

I also want to speak candidly to stockholders who have been with Super League for some time.

We have made real progress over the past year. But leading up to the announcement of this transaction, that progress had not yet translated into the public-market value that stockholders have hoped we would achieve. That has been frustrating for all of our stakeholders, including you, as well as for our employees and certainly for me.

We could have kept working inside those constraints. Instead, we chose to try to change them.

This transaction would not guarantee an outcome. Bitcoin will fluctuate. Capital markets will shift. Our execution will matter enormously, and the transaction itself remains subject to our stockholders’ approval and other closing conditions. Yet in sum, I believe the ceiling on what Super League can become as Superplanet would be significantly transformed.

Upon closing, we would no longer be defined solely by the scale of our current business. We would have a meaningful Bitcoin treasury, the backing of one of the largest corporate Bitcoin holders globally, and a platform spanning Nasdaq and the Tokyo Stock Exchange.

The Journey Ahead

For stockholders who have stayed with us through the harder chapters, I believe this transaction is what we have worked hard to earn: a path to a larger future, not just a bigger balance sheet.

Our ambition isn’t simply to own Bitcoin. Rather, it’s to build Superplanet into a company that combines disciplined capital allocation, an operating business with growth in its future, and the full weight of Metaplanet behind us as a majority stockholder for the long-term.

There is substantial work in front of us, and there will be volatility along the way. But for the first time in several years, we have a business positioned to compete for capital at a scale we would be less likely to achieve on an isolated path.

Your vote at our Annual Meeting on October 16, 2026 is how this future happens. With our definitive proxy statement now available, this letter is meant to express why I personally believe in what we are pursuing through this transaction and share my conviction that the proposals in front of you deserve your support.

Voting

For your convenience, contact information for our proxy solicitor is immediately below. They can assist in the voting process:

Advantage Proxy, Inc.
Toll Free: 1-877-870-8565
Collect: 1-206-870-8565
Email: ksmith@advantageproxy.com 

In closing, I am deeply grateful to our stockholders, to the team members whose work propelled us to this moment, and to Metaplanet for the confidence it has placed in our team.

Super League built the foundation. Superplanet would give us the chance to scale on top of it — together.

Matt Edelman
Chairman, Chief Executive Officer & President
Super League Enterprise, Inc.

About Super League

Super League (Nasdaq: SLE) connects brands with the 3.3 billion-person global gaming population through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this highly engaged yet under-monetized audience, Super League is positioned to capture an increasing share of brand advertising spend as the market evolves.

Important Information About the Annual Meeting and Where to Find It

The Company has filed a definitive proxy statement with the SEC on September 25, 2026 in connection with its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company may also file other documents with the SEC in connection with the Annual Meeting. This document is not a substitute for the definitive proxy statement or any other document which the Company may file with the SEC. Investors and stockholders are urged to read the definitive proxy statement and any other relevant documents that are or will be filed with the SEC, as well as any amendments or supplements thereto, carefully and in its entirety because they contain or will contain important information regarding the proposals to be considered at the Annual Meeting, the proposed transaction with Metaplanet (the “Metaplanet Transaction”) and related risks and matters. The definitive proxy statement and other filings are available free of charge through the SEC’s website.

Participants in the Solicitation

Super League and certain of its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies from Super League’s stockholders in connection with the Metaplanet Transaction. Additional information regarding the identity of the participants, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement and other materials filed with the SEC in connection with the Metaplanet Transaction. You may obtain copies of these documents filed with, or furnished to, the SEC free of charge. All such documents are available free of charge at the SEC’s website at www.sec.gov or Super League’s website at www.superleague.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements include all statements other than statements of historical fact, including, without limitation, all statements regarding the Metaplanet Transaction; the value of Bitcoin received by Super League in exchange for the shares of Super League common stock to be issued to Metaplanet; Super League’s value, assuming the consummation of the Metaplanet Transaction; Super League becoming controlled by Metaplanet following the closing of the Metaplanet Transaction; Super League’s new business strategy regarding a Bitcoin treasury model; Super League’s ability to raise capital after the consummation of the Metaplanet Transaction, including the sale of preferred shares to purchase additional Bitcoin; terms of potential preferred stock to be issued should the Metaplanet Transaction be consummated; publishing of Bitcoin-related metrics after the consummation of the Metaplanet Transaction; the transaction structure and key terms of the Metaplanet Transaction; and the approval by Super League’s stockholders in connection with the Metaplanet Transaction; Super League’s ability to maintain compliance with the Listing Rules of the Nasdaq Capital Market; strategic transactions and partnerships; and capital structure, liquidity, and financing activities. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which the Company operates, management’s current beliefs, and certain assumptions made by the Company, all of which are subject to change.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these are based only on Super League’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other conditions. Because forward-looking statements relate to the future, these are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Super League’s control. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results or financial condition to differ materially from those indicated in any forward-looking statements. Neither Super League nor any other person assume responsibility for the accuracy and completeness of the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events.

Important risk factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to: fluctuations in the market price of bitcoin and any associated unrealized gains or losses on digital assets, including accounting treatment relating to the Company’s bitcoin holdings; changes in securities laws or other laws or regulations, or the adoption of new laws or regulations, relating to bitcoin that adversely affect the price of bitcoin or Super League’s ability to transact in or own bitcoin; the impact of the availability of spot exchange traded products and other investment vehicles for bitcoin and other digital assets; a decrease in liquidity in the markets in which bitcoin is traded; security breaches, cyberattacks, unauthorized access, loss of private keys, fraud or other circumstances or events that result in the loss of Super League’s bitcoin; impacts to the price and rate of adoption of bitcoin associated with financial difficulties and bankruptcies of various participants in the digital asset industry; the extent and timing of market acceptance of Super League’s new product offerings; the Company’s ability to create customer demand and adoption trends; the Company’s ability to successfully integrate new technologies and partnerships; the consummation of the Metaplanet Transaction on anticipated terms and timing, including the satisfaction of closing conditions; the Company’s ability to maintain compliance with the Nasdaq Capital Market continued listing standards; access to, and the cost of, capital; and the other risks and uncertainties described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s Definitive Proxy Statement on Schedule 14A, and other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Any forward-looking statement made by the Company in this press release is based only on information currently available to Super League and speaks only as of the date on which it is made. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Allan Rosenthal
Intelligent IR ATX
abrosey@intelligentiratx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) will issue its third-quarter 2026 financial and operating results before the markets open on October 30, 2026.

CN’s senior officers will review the results and the railway’s outlook in a conference call starting at 8:30 a.m. Eastern Time on October 30. Tracy Robinson, CN President and Chief Executive Officer, will lead the call.

Parties wishing to participate via telephone may dial 1-800-715-9871 (Canada/U.S.), or 1-647-932-3411 (International), using 5186426 as the passcode. Participants are advised to dial in 10 minutes prior to the call.

CN will webcast the presentation live and furnish slides supporting the officers’ remarks via the Investors section of its website at www.cn.ca/investors. A webcast replay will be available after the call ends.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:
Media	Investment Community
Ashley Michnowski	Jamie Lockwood
Senior Manager	Vice-President
Media Relations	Investor Relations & Special Projects
(438) 596-4329	(514) 399-0052
media@cn.ca	investor.relations@cn.ca

Company Adds 30-Year IBM Executive and Operations Expert to Board

Fort Lauderdale, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – a diversified holding company and owner of Azure Holdings, a renewable power plant developer, and SemiCab Holdings, an AI-enabled logistics provider, today formally introduced its newest independent director, Greg Smith.

Mr. Smith is a highly accomplished executive in the technology industry, having spent his entire professional career with IBM. In the later years of his tenure at IBM, Mr. Smith managed multi-country organizations with direct responsibility for an annual budget of $2 billion.

Mr. Smith was recognized for his management acumen early in his career, having been promoted to an engineering management position within three years of joining IBM. Over the ensuing 30 years, Mr. Smith assumed progressively greater managerial roles within the organization, with a focus and area of expertise on business process management, and received both his PMI project management certification and IBM Project Management Executive Certification. Mr. Smith has received various IBM recognitions, including a Global Supply Chain Leadership Award. Mr. Smith received his BS in Aeronautics and a Master of Business Administration from San Jose State University.

“We are pleased to formally welcome Greg to our Board of Directors,” commented Andrew Thompson, our CEO. “Greg brings a tremendous understanding of organizational structure, as well as of creating and managing high-value client relationships. Most importantly, we expect he will help us establish a strong focus on accountability and a results-driven culture across the Algorhythm portfolio of companies.”

“In addition, Greg was a key part of the technology ecosystem that rapidly grew from the 1990s to the 2010s. He has a deep understanding of the macro forces driving the AI data center boom, and we believe his insights will be invaluable as we seek new growth opportunities to deliver power to data center infrastructure sites across the United States using our renewable biomass power plant solutions,” concluded Mr. Thompson.

About Algorhythm Holdings

Algorhythm Holdings, Inc. is a holding company with two primary assets, Azure Holdings and SemiCab Holdings. Azure Holdings, dba Azure Energy (“Azure”), is a developer of renewable biomass power generation infrastructure. Its team, including its co-founders, consists of some of the most experienced biomass power plant experts in the U.S. today. Collectively, this team has designed and built 72 facilities generating 17.5 GW of renewable power to date. Azure was launched in 2025 and has already secured equity participation, which management estimates to have a net present value of over $220 million, in multiple power plants currently under construction in the U.S. Azure has significant fee-based consulting revenues under multi-year contracts and is generating positive EBITDA. For additional information, please go to: http://www.azure-energy.co.

Algorhythm Holdings, Inc. also owns and operates SemiCab, an AI-enabled logistics software provider. Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform is designed to provide the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML predictions and advanced predictive optimization models to enable fully loaded round trips. With SemiCab’s AI platform, shippers pay less and carriers make more without having to change a thing. For additional information, please go to: http://www.semicab.com.

Investor Relations Contact

Brendan Hopkins
407-645-5295
investors@algoholdings.com
www.algoholdings.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “seeks,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding Mr. Smith’s expected contributions to the Company, the Company’s growth opportunities, including in supplying power to data center infrastructure, and the estimated value of Azure’s equity participation in power plants under construction. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation, the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.

SSCP Lager BidCo AB (publ) (“SSCP Lager BidCo” or the “Issuer”) today announces that the Issuer is exercising its right to make a conditional voluntary total redemption of its outstanding senior secured floating rate notes 2023/2026 with ISIN SE0021021193 (the “Notes” and the “Redemption”), in accordance with the terms and conditions of the Notes.

The redemption date of the Redemption will be 30 October 2026 (the “Redemption Date”). The Notes will be redeemed at an amount equal to 100.78125 per cent. of the nominal amount per Note (the “Redemption Price”), together with any accrued and unpaid interest. The Redemption Price, together with accrued and unpaid interest, will be paid to each person who is registered as owner of Notes in the debt register maintained by Euroclear Nordics AB at end of business on 23 October 2026 (the “Record Date”). In connection with the Redemption, the Notes will be delisted from Nasdaq Stockholm’s corporate bond list.

The Redemption is conditional upon the successful execution of a facilities agreement with, inter alios, certain lenders and the Issuer being content that the conditions for utilisation of the facilities provided in the facilities agreement will be satisfied no later than on the Redemption Date (the “Condition”). The Issuer shall not, and has no obligation to, redeem any of the Notes unless the Condition has been fulfilled or waived by the Issuer on or prior to the Record Date. The Issuer will by way of a press release inform whether or not the Condition have been met or waived or will not be satisfied.

The notice of conditional voluntary total redemption of the Notes is available on SSCP Lager BidCo’s website, via the following link: https://logentgroup.com/en/investor-relations/

For further information, please contact:

Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se

Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se

This information is information that SSCP Lager BidCo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 6 October 2026, at 14:54 CEST.

About Logent Group
Logent is a comprehensive and independent logistics partner, with a Nordic base and with global networks. We have a wide range of services and create value for our customers through guaranteed cost and quality improvements. Our services include Logistics Services such as Warehouse Management, Transport Management and Customs, Port and Combined Terminals, Staffing Services and Consulting Services. This means that Logent has grown to a turnover of about SEK 3 billion from the start in 2006 and employs approximately 3,300 people.

Attachment

• SSCP Lager BidCo AB (publ)_06102026_en.pdf

The demonstration represents another development milestone in the Company’s development of quantum-enabled platform for high-dimensional clinical data analysis 

Tel Aviv, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (Nasdaq: QXL) (“Quantum X” or the “Company”), an advanced technologies company, today reported its GPU-accelerated quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only CPU implementation.

The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.

Quantum X’s proprietary algorithm, operated through its subsidiary CliniQuantum, searched for correlated three-gene configurations across the dataset. The 3,531 genes generated 7,331,162,245 possible three-gene combinations. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.

The analysis required approximately 8.4 hours using 64 vCPUs, compared with approximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while producing the same qualifying gene-triplet results.

“This represents an important development milestone for Quantum X Labs,” said Dr. Tidhar Turgeman, head of clinical trials data analysis. “Clinical and molecular datasets can contain thousands of variables but relatively few patients, creating enormous combinatorial search spaces. Demonstrating the ability to evaluate more than 7.3 billion potential gene combinations on real clinical data marks an important step in our development. The significant GPU acceleration further supports our continuing development of scalable, quantum-enabled approaches for biomarker discovery and patient stratification.”

The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using IBM Qiskit Aer GPU-based quantum simulation, with an NVIDIA T4 Tensor Core GPU. The benchmark was designed to evaluate computational performance and did not evaluate or establish the clinical validity, predictive value, or potential utility of any identified gene combinations.

QuantumXLabs intends to continue advancing its algorithms toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets, while progressing its development pathway from simulation and validation toward execution on quantum computing hardware.

Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the continued development and optimization of its technologies, the expansion of its research and development activities, potential applications of its solutions, the advancement of its business strategy, and its expectations regarding future performance and growth opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites. 

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com

Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston

CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center.

The meeting will take place October 6–8, 2026, on MD Anderson’s campus in Houston, Texas. The presentation will highlight ERNA-101’s potential to address a fundamental challenge in ovarian cancer: the immunosuppressive tumor microenvironment that can limit effective antitumor immune responses. In preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment and was associated with significant tumor regression and enhanced survival. When combined with PD-1 checkpoint blockade, ERNA-101 demonstrated enhanced antitumor activity, including complete tumor control and durable responses in the majority of treated animals.

“Selection for presentation at a Nature Conferences meeting co-hosted by MD Anderson Cancer Center highlights the strength of our preclinical findings for ERNA-101, and we look forward to engaging with researchers and oncology leaders focused on advancing the next generation of cancer therapies,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “Our data demonstrate the potential of our allogeneic, off-the-shelf approach to deliver immune-activating cytokines to the tumor microenvironment, recruit key immune cells and enhance the activity of checkpoint blockade. We believe these findings provide a strong scientific foundation for advancing ERNA-101 toward the clinic and investigating its potential to address the significant unmet need in ovarian cancer.”

Presentation Details

Title: IL7-IL15-iMSCs (ERNA-101): Allogeneic, Off-the-Shelf, Next-Generation Immune-Enhancing Cell Therapy of Cancer
Session: Flash Talk Date: Tuesday, October 6, 2026
Location: The University of Texas MD Anderson Cancer Center, Houston, Texas

The presentation will feature preclinical findings demonstrating ERNA-101’s ability to recruit T cells and proinflammatory macrophages and promote an immune-active tumor microenvironment in models of high-grade serous ovarian cancer. In combination with PD-1 checkpoint blockade, ERNA-101 achieved complete tumor control and durable responses in the majority of treated animals, with the findings reproduced in a larger cohort. Biodistribution studies also showed localization of ERNA-101 to the tumor microenvironment, with no detectable signal in the peritoneal wash, serum or other organs evaluated.

Co-hosted by Nature Conferences and MD Anderson Cancer Center, the Next-Generation Cancer Therapeutics meeting will bring together researchers from academia, biotechnology and the pharmaceutical industry to discuss emerging approaches to cancer treatment, including next-generation biologics, immunotherapies, targeted therapies and novel therapeutic platforms. For more information, please visit the conference website.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About ERNA-101

ERNA-101 is Ernexa’s lead oncology program, comprising allogeneic, off-the-shelf, induced pluripotent stem cell-derived mesenchymal stromal cells (iMSCs) engineered to express IL-7 and IL-15 as a single fusion protein (IL-7_IL-15-fusokine). ERNA-101 is designed to deliver an immune-activating cytokine payload to the tumor microenvironment, promote antitumor immune responses and potentially enhance the activity of checkpoint blockade. Ernexa is advancing ERNA-101 toward clinical development for ovarian cancer.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to advance ERNA-101 toward and submit an IND application to the FDA, including the planned submission in Q4 2026; the timing, design and outcomes of the planned first-in-human clinical study of ERNA-101 in platinum-resistant ovarian cancer, including the expected availability of clinical data in Q4 2027; the Company’s ability to transition from a preclinical-stage company to a clinical-stage company; expectations regarding the versatility and therapeutic potential of the Company’s synthetic iMSC platform, including its ability to be engineered for distinct therapeutic purposes across oncology and other disease areas; the Company’s plans to broaden its oncology pipeline by evaluating additional high-need cancer indications and advancing next-generation iMSC candidates; the Company’s ability to identify, develop and advance additional product candidates; the Company’s capital allocation strategy, including the decision to pause additional preclinical development expenditures on ERNA-201 and concentrate near-term resources on ERNA-101 and oncology pipeline expansion; the potential for ERNA-201 to be advanced in the future; the Company’s ability to enter into strategic collaborations or partnerships; the sufficiency of the Company’s capital resources to fund planned operations and achieve anticipated milestones; the Company’s ability to obtain and maintain regulatory approvals for its product candidates; the Company’s ability to attract and retain qualified personnel; the Company’s ability to protect its intellectual property and proprietary technology; competition from other companies developing therapies for the same or similar indications; and general market, political and economic conditions. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Dogwood recently announced the completion of enrollment in its Halneuron^® Phase 2b Trial and anticipates topline data readout of the study in November 2026.

Portions of the event will also be streamed online at https://digital.maximgrp.com/. For registration information and a complete agenda of the Maxim Growth Summit, click here.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com